Drug interactions
Nirsevimab + Palivizumab
Severity: Moderate
Nirsevimab and Palivizumab: moderate interaction.
Last updated
For healthcare professionals — reference only. This page is a brief summary, not medical advice and not a substitute for official labeling or clinical judgement. Always verify before prescribing or dispensing.
Summary
Both are monoclonal antibodies that provide passive RSV protection and are used for the same indication. Giving both offers no added benefit and exposes the infant to unnecessary dosing.
What this interaction means in plain words
Nirsevimab and Palivizumab can affect each other. The combination is often manageable, but it may need a change of dose, a change of timing, or extra checks while both are taken.
Nirsevimab belongs to Miscellaneous; Palivizumab belongs to Miscellaneous.
Why it happens
Therapeutic duplication of RSV F-protein-targeting antibodies; no pharmacokinetic interaction is established.
What to do
Do not give palivizumab to infants who have already received nirsevimab in the same RSV season. For infants who had palivizumab first, follow the labeled guidance on switching.
What to ask your pharmacist
- Should I take them at different times of day?
- Does the dose of either medicine need to change?
- Is there anything I should avoid, such as alcohol or certain foods, while on both?
Pro+ members
Unlock the full page
Create an account and start a Pro+ trial to unlock the full management advice for Nirsevimab and Palivizumab, the additional notes, the evidence detail and the whole-prescription interaction checker.
- Full clinical management advice
- Additional notes
- Evidence detail
- Interaction checker for a whole prescription
Try Pro+ free for 14 days on the web. No card needed.
Frequently asked questions
Can I take Nirsevimab with Palivizumab?
MediHelp rates the interaction as moderate. Nirsevimab and Palivizumab can affect each other. The combination is often manageable, but it may need a change of dose, a change of timing, or extra checks while both are taken. Both are monoclonal antibodies that provide passive RSV protection and are used for the same indication. Giving both offers no added benefit and exposes the infant to unnecessary dosing.
How serious is the interaction between Nirsevimab and Palivizumab?
MediHelp rates it moderate, on a four-level scale (minor, moderate, major, contraindicated) based on published labels and references. What to do, in brief: Do not give palivizumab to infants who have already received nirsevimab in the same RSV season. For infants who had palivizumab first, follow the labeled guidance on switching.
Full monographs, dosing and an interaction checker in the MediHelp app
Open the complete reference, check multi-drug interactions and use dosing tools in the MediHelp app.
